Reduced neuroprotection and risk for bleeding with drotrecogin-alfa activated compared with 3K3A-APC mutant after transient MCAO. Vehicle, drotrecogin-α (0.5 and 2 mg/kg) and 3K3A-APC (0.4 and 2 mg/kg) were administered through the femoral vein 5 minutes before 1 hour MCAO. Neuropathological analysis, neurological motor score, and hemoglobin levels were determined at 24 hours of reperfusion. A, Infarct volume. B, Brain swelling (edema). C, Motor neurological score. D, Hemoglobin levels in ischemic hemisphere. Mean ± SEM, n=6 mice per group.